首页> 美国卫生研究院文献>Annals of the Rheumatic Diseases >Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two 138‐week randomised studies of patients with osteoarthritis

【2h】

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two 138‐week randomised studies of patients with osteoarthritis

机译：在两项为期138周的骨关节炎患者随机研究中评估了依托考昔与萘普生相比的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesTo assess the efficacy and safety of etoricoxib 60 mg once daily and naproxen 500 mg twice daily over a 138‐week treatment period in patients with osteoarthritis (OA).

机译：目的评估在138周的治疗期间对骨关节炎（OA）患者而言，每天一次60mg依托昔布和每天两次500mg萘普生的疗效和安全性。

著录项

期刊名称 Annals of the Rheumatic Diseases
作者
J Y Reginster; K Malmstrom; A Mehta; G Bergman; A T Ko; S P Curtis; A S Reicin;
展开▼
作者单位

展开▼
年(卷),期 2007(66),7
年度 2007
页码 945–951
总页数 7
原文格式 PDF
正文语种
中图分类免疫性疾病;
关键词
COX‐2 selective inhibitors NSAIDs osteoarthritis etoricoxib naproxen;

机译：COX-2选择性抑制剂;NSAID;骨关节炎;依托昔布;萘普生;

相似文献

外文文献
中文文献
专利

1. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: A randomized, double-blind, parallel-group, multicenter study† [J] . Christoph Baerwald, Paolo Verdecchia, Brigitte Duquesroix, Arthritis & Rheumatism . 2010,第12期

机译：与安慰剂和萘普生500 mg萘普生相比，髋骨关节炎患者每天两次750 mg的疗效，安全性和对血压的影响：一项随机，双盲，平行组，多中心研究†< / sup>
2. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. [J] . Baerwald C, Verdecchia P, Duquesroix B, Arthritis and Rheumatism . 2010,第12期

机译：与髋关节骨关节炎患者相比，每天两次750 mg萘普生与安慰剂和每天两次500 mg萘普生的疗效，安全性和对血压的影响：一项随机，双盲，平行组，多中心研究。
3. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study. [J] . Baerwald C, Verdecchia P, Duquesroix B, Arthritis and Rheumatism . 2010,第12期

机译：与髋关节骨关节炎患者相比，每天两次750 mg萘普生与安慰剂和每天两次500 mg萘普生的疗效，安全性和对血压的影响：一项随机，双盲，平行组，多中心研究。
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. The early external cephalic version (ECV) trial: A randomised controlled trial of ECV beginning at between 34--36 weeks compared to 37--38 weeks gestation. [D] . Hutton, Eileen Katherine McNally. 2003

机译：早期体外头颅试验（ECV）：一项ECV随机对照试验始于妊娠34--36周，而妊娠37--38周。
6. The IPSO study: ibuprofen paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip [O] . F Boureau, H Schneid, N Zeghari, 2004

机译：IPSO研究：布洛芬对乙酰氨基酚在骨关节炎中的研究。一项随机比较的临床研究比较了布洛芬和扑热息痛止痛药治疗膝盖或髋部骨关节炎的疗效和安全性
7. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis [O] . Reginster, Jean-Yves, Malmstrom, K., Mehta, A., 2007

机译：在两项为期138周的骨关节炎患者随机研究中评估依托洛昔布与萘普生相比的疗效和安全性

Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two 138‐week randomised studies of patients with osteoarthritis

摘要

著录项

相似文献

相关主题

期刊订阅